

This is a promotional advertisement from LEO Pharma for UK healthcare professionals.

For the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.¹

**Adtralza**[®]
(tralokinumab)

Indicated for adult
and adolescent
patients 12 years
and older¹



TIME TO PRESS PLAY



Not an actual patient. For illustrative purposes only. Individual results may vary.

**Adtralza[®] – The first licensed biologic that inhibits IL-13 alone,^{1,2}
a key driver of atopic dermatitis signs and symptoms.³**

For more information visit WWW.ADTRALZA.CO.UK

IL, interleukin.

Prescribing Information for Adtralza[®] (tralokinumab) 150 mg solution for injection in pre-filled syringe

Please refer to the full Summary of Product Characteristics (SmPC) (www.medicines.org.uk/emc) before prescribing.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. **Indications:** Treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy. **Active Ingredients:** Each pre-filled syringe contains 150 mg of tralokinumab in 1 mL solution (150 mg/mL). **Dosage and administration:** Posology: The recommended dose of tralokinumab for adult and adolescent patients 12 years and older is an initial dose of 600 mg (four 150 mg injections) followed by 300 mg (two 150 mg injections) administered every other week as subcutaneous injection. Every fourth week dosing may be considered for patients who achieve clear or almost clear skin after 16 weeks of treatment. Consideration should be given to discontinuing treatment in patients who have shown no response after 16 weeks of treatment. Some patients with initial partial response may subsequently improve further with continued treatment every other week beyond 16 weeks. Tralokinumab can be used with or without topical corticosteroids. The use of topical corticosteroids, when appropriate, may provide an additional effect to the overall efficacy of tralokinumab. Topical calcineurin inhibitors may be used, but should be reserved for problem areas only, such as the face, neck, intertriginous and genital areas. If a dose is missed, the dose should be administered as soon as possible and then dosing should be resumed at the regular scheduled time. No dose adjustment is recommended for elderly patients, patients with renal impairment or patients with hepatic impairment. For patients with high body weight (>100 kg), who achieve clear or almost clear skin after 16 weeks of treatment, reducing the dosage to every fourth week might not be appropriate. The safety and efficacy of tralokinumab in children below the age of 12 years have not yet been established. **Method of administration:** Subcutaneous use. The pre-filled syringe should not be shaken. After removing the pre-filled syringes from the refrigerator, they should be allowed to reach room temperature by waiting for 30 minutes before injecting. Tralokinumab is administered by subcutaneous injection into the thigh or abdomen, except the 5 cm around the navel. If somebody else administers the injection, the upper arm can also be used. For the initial 600 mg dose, four 150 mg tralokinumab injections should be administered consecutively in different injection sites within the same body area. It is recommended to rotate the injection

site with each dose. Tralokinumab should not be injected into skin that is tender, damaged or has bruises or scars. A patient may self-inject tralokinumab or the patient's caregiver may administer tralokinumab if their healthcare professional determines that this is appropriate.

Contraindications: Hypersensitivity to the active substance or to any of the excipients. **Precautions and warnings:** If a systemic hypersensitivity reaction (immediate or delayed) occurs, administration of tralokinumab should be discontinued and appropriate therapy initiated. Patients treated with tralokinumab who develop conjunctivitis that does not resolve following standard treatment should undergo ophthalmological examination. Patients with pre-existing helminth infections should be treated before initiating treatment with tralokinumab. If patients become infected while receiving tralokinumab and do not respond to anthelmintic treatment, treatment with tralokinumab should be discontinued until infection resolves. Live and live attenuated vaccines should not be given concurrently with tralokinumab. **Fertility, pregnancy and lactation:** There is limited data from the use of tralokinumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of tralokinumab during pregnancy. It is unknown whether tralokinumab is excreted in human milk or absorbed systemically after ingestion. Animal studies did not show any effects on male and female reproductive organs and on sperm count, motility and morphology. **Side effects:** Very common ($\geq 1/10$): Upper respiratory tract infections. Common ($\geq 1/100$ to $< 1/10$): conjunctivitis, conjunctivitis allergic, eosinophilia, injection site reaction. Uncommon ($\geq 1/1,000$ to $< 1/100$): keratitis. **Precautions for storage:** Store in a refrigerator (2°C-8°C). Do not freeze. Store in the original package in order to protect from light. **Legal category:** POM. **Marketing authorisation number and holder:** PLGB 05293/0182, EU/1/21/1554/002. LEO Pharma A/S, Ballerup, Denmark. **Basic NHS price:** 4 pre-filled syringes: £1,070 (each syringe contains 150 mg/mL). **Last revised:** November 2022 **Reference number:** REF-22455

Reporting of Suspected Adverse Reactions

Adverse events should be reported.

Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to Drug Safety at LEO Pharma by calling +44 (0)1844 347333 or e-mail medical-info.uk@leo-pharma.com

References: 1. Adtralza[®] SPC. 2. Duggan S. *Drugs* 2021;81(14):1657–1663. 3. Bieber T. *Allergy* 2020;75:54–62.



Further information can be found in the Summary of Product Characteristics or from:






LEO Pharma, Horizon, Honey Lane, Hurley, Berkshire SL6 6RU.

E-mail: medical-info.uk@leo-pharma.com

® Registered trademark

Date of preparation: January 2023
UK/MAT-62945

Male pattern hair loss: Can developmental origins explain the pattern?

Leah C. Redmond¹  | Summik Limbu¹  | Bessam Farjo²  | Andrew G. Messenger³  |
Claire A. Higgins¹ 

¹Department of Bioengineering, Imperial College London, London, UK

²Farjo Hair Institute, Manchester, UK

³Department of Dermatology, University of Sheffield, Sheffield, UK

Correspondence

Claire A. Higgins, Department of Bioengineering, Imperial College London, London, UK.

Email: c.higgins@imperial.ac.uk

Funding information

Engineering and Physical Sciences Research Council; ISHRS

Abstract

Male pattern hair loss (MPHL), also referred to as male androgenetic alopecia (AGA) is the most common type of non-scarring progressive hair loss, with 80% of men suffering from this condition in their lifetime. In MPHL, the hair line recedes to a specific part of the scalp which cannot be accurately predicted. Hair is lost from the front, vertex, and the crown, yet temporal and occipital follicles remain. The visual effect of hair loss is due to hair follicle miniaturisation, where terminal hair follicles become dimensionally smaller. Miniaturisation is also characterised by a shortening of the growth phase of the hair cycle (anagen), and a prolongation of the dormant phase (kenogen). Together, these changes result in the production of thinner and shorter hair fibres, referred to as miniaturised or vellus hairs. It remains unclear why miniaturisation occurs in this specific pattern, with frontal follicles being susceptible while occipital follicles remain in a terminal state. One main factor we believe to be at play, which will be discussed in this viewpoint, is the developmental origin of the skin and hair follicle dermis on different regions of the scalp.

KEYWORDS

pattern hair loss, skin ageing, skin development

1 | AN INTRODUCTION TO PATTERNED HAIR LOSS

The hair follicle continuously cycles through three phases during its lifetime: anagen (growth phase—elongation of growing hair fibre), catagen (regression phase—formation of club hair fibre) and telogen (resting phase—retention of club hair fibre). At the end of telogen the club fibre is actively shed in a process termed exogen, while the follicle itself re-enters anagen to start production of a new growing hair fibre.¹ On the scalp of young non-bald men, anagen typically lasts at least 2 years,² catagen 2 weeks and telogen around 2–3 months.³ In male pattern hair loss (MPHL), the phenotype observed as an effect of androgenetic alopecia (AGA) in males, follicles undergo miniaturisation in a localised pattern.⁴ Specifically, follicles in the skin above

the frontal and parietal bones of the skull vault undergo miniaturisation leading to what is described as a Norwood-Hamilton pattern of MPHL. These miniaturising follicles experience a decreased duration of anagen, an increased duration of telogen⁵ and often the prolongation of a phase known as kenogen wherein the club fibre is shed during exogen yet the follicle remains 'stuck' in telogen.⁶ Collectively, these changes contribute to the appearance of a balding phenotype due to an overall decrease in hair fibre width and pigmentation. In contrast, follicles in skin above the occipital and temporal bones of the skull vault do not undergo miniaturisation—these are termed occipital or non-miniaturising follicles within this viewpoint.

The clinical presentation of MPHL is driven by miniaturisation of the hair follicle. While MPHL is androgen dependent and predominantly driven by genetics, the aetiology is much less

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2023 The Authors. *Experimental Dermatology* published by John Wiley & Sons Ltd.

well-defined in the female equivalent of the trait, female pattern hair loss (FPHL). There are also many other differences between FPHL and MPHL, the most well described of which is the pattern of miniaturisation. In women, it is the follicles nearest the parting at the centre of the scalp which undergo miniaturisation with a diffuse pattern, giving rise to what was described by Olsen as a Christmas tree pattern of hair loss.⁷ There can also be occipital involvement, termed diffuse unpatterned alopecia,⁸ in some but not all cases of FPHL. In MPHL, there is a highly significant association of the androgen receptor (AR) locus (Xq11-12) with early onset of the trait in a Norwood Hamilton pattern.⁹ In FPHL, studies in German and Chinese cohorts have not identified an association of the AR locus with FPHL.^{10,11} A nominally significant SNP in AR has been identified in a British population, however this was only associated with early onset FPHL.¹¹

In addition to the AR locus, another locus which has been identified as strongly associated with MPHL is 20p11, first identified in a Suisse cohort and validated in British, Icelandic and Dutch populations.¹² A later study in a German cohort, with men exhibiting the Norwood-Hamilton pattern of MPHL, corroborated these results.⁹ Building on this were studies in a Chinese¹³ and Korean¹⁴ cohorts which also associated 20p11 locus with MPHL. In FPHL, no association has been made to date, with the 20p11 locus in any cohort.¹⁵

While PAX1 is located at the 20p11 location, other genes including *FOXA2*,¹² *HDAC9*^{16,17} and *EDAR*¹⁸ have also been significantly associated with MPHL. In addition to Xq11-12, additional MPHL risk loci have also been identified on the X-chromosome, encompassing genes such as *FAM9A*, *FAM9B*, *KLF8* and *TRIS2*.¹⁸ Functional interactions are now starting to be made between genes identified in MPHL GWAS¹⁹; however, to our knowledge these have not yet been investigated in FPHL.

2 | THE MECHANISM OF MINIATURISATION

The role of androgens in MPHL has been well-established as castrated males (who lack androgens) do not exhibit follicle miniaturisation.²⁰ This was explored in 1960, where 21 young adult males were castrated and monitored for signs of MPHL for 18 years following their castration. Subjects who had no hair loss at the time of castration kept their full head of hair, with those already showing slight frontal hair loss showing no further hair loss.

In contrast, exposure of castrated men with a family history of MPHL to androgens can lead to follicle miniaturisation.²¹ Given the stark appearance of the Norwood-Hamilton pattern in most cases of MPHL and the well-documented association with the AR, we will focus specifically on MPHL (as opposed to FPHL) from hereon as a form of AGA in this viewpoint discussing the pattern of hair loss.

In MPHL, the process of miniaturisation is triggered by the conversion of androgens such as circulating testosterone to their more potent form dihydrotestosterone (DHT), by 5 α reductase type I and type II. Re-analysis of published scRNA-seq data of human hair

follicles in anagen²² reveals that 5 α reductase II is expressed exclusively in the dermal papilla (DP), while 5 α reductase I is expressed within cells both in the hair follicle dermis and hair follicle epithelium (Figure 1A). Once testosterone is converted to DHT it acts on the follicle by binding to cytoplasmic AR, which dimerises with another DHT-bound AR. Since AR is only expressed within the DP and dermal sheath of anagen hair follicles (Figure 1A), this dimerization of the DHT-bound AR occurs in the hair follicle dermis. The dimerised complex then enters the nucleus and binds to promoters of androgen targets, leading to the expression of genes including *TGF- β 1*, *TGF- β 2*, *DKK-1* and *IL-6* and subsequent transformation of large terminal follicles to a miniaturised vellus state.²³

Within the hair follicle 5 α reductase II and the AR gene are expressed within the DP,^{24,25} a flame shaped structure located at the base of the follicle containing specialised fibroblasts. DP cells have key roles in hair growth, including initiation of the anagen phase²⁶ and signalling for directed differentiation of the epithelial hair matrix.^{27,28} The diameter of the DP is positively correlated with the diameter of the hair shaft produced by the follicle matrix.²⁹ While the size of the DP is relatively static during anagen, it decreases in catagen and telogen due to a cell efflux, before increasing in size again at the start of a new anagen due to cell influx from the follicle dermal sheath stem cells.³⁰ A key feature of miniaturised follicles in MPHL is that their DP become smaller.²⁹ This miniaturisation of the DP does not occur during anagen per se, but instead it occurs when the follicle cycles,³¹ suggesting that a perturbation in the efflux or influx processes regulate DP size in MPHL.³²

MPHL can additionally be characterised by replacement of the arrector pili muscle (APM) in the follicle with fat tissue.³³ The APM in non-balding hair follicles has a branched attachment to all follicles within a follicular unit, whilst APM attachment is lost to miniaturised follicles in AGA follicular units.^{33,34} Miniaturising follicles show a higher fat:APM ratio, suggesting that fat replacement of the APM is progressive with time. The presence of an APM also enables distinction between miniaturised hair follicles and vellus hair follicles on the face, which have an APM.³⁵ Interestingly, in mice, hair follicle stem cells (HFSC) act as a niche for the APM, depositing extracellular matrix which guides the attachment of the APM at the bulge region of the follicle.³⁶ While the number of HFSC is not reduced in MPHL, their ability to differentiate into progenitors is impaired.³⁷ It is unclear however if impairment of signalling from HFSC is what determines the replacement of the APM in MPHL.

As mentioned earlier in this piece, in MPHL, follicle miniaturisation occurs in a specific pattern on the frontal scalp. In hair transplant surgery to treat MPHL, occipital (non-miniaturising) follicles are surgically relocated to the frontal scalp to cover the balding area. Experimental observations by Orentreich in the 1950s indicated that relocated hair follicles do not undergo miniaturisation post repositioning despite the levels of androgens being higher in the frontal scalp.³⁸ This phenomenon is termed 'donor dominance'³⁹ and suggests susceptibility to miniaturisation is a trait that is intrinsic to the follicle itself rather than something that is driven by localised signalling cascades within the follicle's surroundings.




FIGURE 1 (A) Schematic showing 5 α -reductase II (5 α R-II) and AR expression in human hair follicles. Data re-analysed from Shim 2022.²² (B) Developmental origins of the skull and facial bone alongside androgen sensitivity of the skin dermis in human scalp. Genes locally upregulated are taken from the literature.⁴²⁻⁴⁴ We postulate that the patterning observed in murine development is conserved in humans.

3 | INTRINSIC DIFFERENCES IN THE DP OF MINIATURISING AND NON-MINIATURISING FOLLICLES

There are several intrinsic differences between miniaturising (frontal) and non-miniaturising (occipital) follicles. It has been shown that in MPHL, follicles on the frontal scalp become hypersensitive to androgens—this is speculated to be due to an increased number of AR transcripts within frontal follicle DP.³⁸ The expression of 5 α reductase type I and II is also reported to be increased in frontal follicles although this was from a cohort of just 12 men and women, hence study repetition in a larger cohort would be valuable.³⁸ Higher expression of 5 α reductase type II is also found in other androgen-sensitive DP such as the beard, when compared to androgen-insensitive sites such as the occipital scalp.⁴⁰ Despite both frontal and beard hair follicles containing an increased number of AR transcripts relative to occipital scalp,⁴¹ the inhibitory androgen response on the frontal scalp is different to the stimulatory response observed in beard follicles (Figure 1). Instead of producing terminal hairs like the beard, frontal follicles produce miniaturised hairs post androgen exposure. The paradoxical effect of this hormone is thought to be completely unique in endocrinology.

RNA sequencing of intact DP from frontal scalp miniaturised follicles and occipital scalp terminal hair follicles from individuals with MPHL has revealed large differential gene expression between DP from these sites.²⁴ The authors focused on genes associated with angiogenesis, of which *NOX5* and *HAND1* were reported as having the largest fold change decrease from occipital to frontal DP (2.8-fold and 2.7-fold respectively). Various other studies have assessed cultured DP cells from miniaturising and non-miniaturising sites. These have revealed differential gene expression patterns suggesting maintenance of androgen sensitivity and differential response to

androgens even in culture. Work from Midorikawa and colleagues identified 107 genes as having differing expression levels between balding and non-balding DP in culture—genes including *BMP2* and *EPHRIN A3* were highlighted as downregulated in miniaturising DP.⁴² A study of immortalised DP cells by Chew and colleagues noted *AR* as a candidate gene alongside several other genes identified as upregulated (*TWIST1*, *UBIAD1*, *SRM*, *FRAP1*, *EXOSC10*) or downregulated (*CASZ1*, *PER2*, *TWIST2*, *RNF145*, *AUTS2*, *SSPN* and *MAPT*) in miniaturising versus non-miniaturising DP.⁴³ In other work, single genes such as *SFRP2* have been investigated and identified as downregulated in frontal DP cells compared to occipital DP,⁴⁴ reinforcing the idea that there are intrinsic differences in the DP between different sites on the scalp.

Research has also shown functional differences between frontal and occipital DP, related to their response to therapeutics. One such example is seen with minoxidil, a commonly used therapeutic which acts to prevent miniaturisation in MPHL. In response to minoxidil treatment, DP cultures from miniaturising follicles have increased 5 α reductase activity, relative to non-treated cells. In comparison, in DP cultures from non-miniaturising follicles, minoxidil elicits no change in 5 α reductase activity relative to the untreated baseline.⁴⁵

4 | WHAT LEADS TO INTRINSIC DIFFERENCES BETWEEN FRONTAL AND OCCIPITAL FOLLICLES?

The differences in AR expression and downstream effects of AR target genes described earlier in this piece help in part to explain why follicles miniaturise on the frontal region of the scalp. However, this still does not address the question of why there are these differences in AR expression in the first place. To look at this,

we adjust our perspective to that of embryonic development. All cells in the body derive from three germ layers formed during the process of gastrulation during embryogenesis—these three layers are termed the ectoderm, mesoderm and endoderm. Once committed to one of these germ layers, cells continue to become primed as progenitors for specific cell types, before differentiating to their final state.

In terms of the skin, both the follicular DP fibroblasts and interfollicular fibroblasts arise from the same precursor cell,⁴⁶ meaning they are derived from the same germ layer post gastrulation. However, several lines of evidence suggest that skin fibroblasts have different germ layers of origin depending on their location on the body. Murine and avian data shows that fibroblasts located on the front of the face (whisker pads) are of a neural crest ectodermal origin, while the back of the head and dorsal dermis contain fibroblasts from a paraxial mesoderm origin.^{47–52} In quail chick chimeras, it has been shown that the mesoderm contributes only to the occipital and ear regions on the head.⁵³

Fibroblasts are not the only cell type proposed to arise from differing developmental origins based on their location, as the underlying bone has a similar story. The viscerocranium (facial skeleton and jaw) of avian species is known to be of neural crest origin.^{54,55} The occipital bone of the skull vault is thought to be mesoderm derived, while bones found in the frontal scalp were originally thought to be of a mixed mesoderm and ectoderm origin.⁵⁵ This mixed lineage hypotheses of the frontal region was however disputed a couple of decades later, with the region now firmly believed to be from the neural crest.⁵³

In mice, lineage tracing has shown that neural crest ectoderm derived components of the skull vault are localised in the frontal bone and in a tongue shaped extension along the sagittal suture (central region) of the interparietal bone, while the remainder of the parietal bone and occipital bone are mesoderm derived.⁵² The overlying skin dermis has a comparable neural crest–mesoderm boundary, although skin movement during development means it does not lie directly above the boundary in the underlying bone.⁵²

Assuming conservation of developmental patterning for translation of this to humans one can envisage how the beard dermis, which has parallels with the whisker pad, is of ectodermal origin while the dermis of the occipital scalp has its origins in the mesoderm. While the frontal balding scalp (covering both the frontal and paraxial bone) is in a less well-defined region (Figure 1) consensus in the scientific community is that the frontal region is neural crest ectoderm. The difficulty comes when assessing the parietal region as it is not known if the tongue extension of neural crest along the sagittal ridge observed in mice is evolutionarily conserved in other species. In lieu of the capacity to conduct lineage tracing in humans, one way to investigate the origin of the frontal skin dermis in humans is to look at the intrinsic differences in gene expression in fibroblasts from this site. With the advancement of next generation sequencing technologies and design of elegant computational algorithms to assess the differentiation trajectory of cells in pseudo time, we envisage that one-day researchers will reverse engineer these trajectories and be

able to determine the starting germ layer origin of cells that appear to have, at the cell surface, similar endpoints. Perhaps this too, can help explain the differing response to androgens between frontal and beard hair follicles.

The hypothesis of frontal scalp in humans being of ectodermal lineage has been borne out of extrapolation of observations in other species, and it is difficult to validate in humans where lineage tracing to this extent is not feasible. It is well accepted that there is heterogeneity in fibroblast identity, both within a single body site and across different body sites.^{56,57} This heterogeneity based on developmental origin is also important to consider in the context of hair transplantation, where follicles are relocated from the occipital to the frontal scalp to treat MPHL. Earlier in this piece we introduced the concept of donor dominance—this idea that follicles remember their origin and consequently behave like follicles from their origin location. While we are not aware of any studies that have evaluated gene expression in occipital dermal papillae transplanted to a frontal location, we presume that transplanted papillae would retain their mesoderm lineage profile. This assumption is based on results from heterotopic transplantation experiments in rodents, which showed that whisker papillae transplanted to an ear location would retain their whisker properties and induce formation of whisker-like follicles in the ear epidermis.⁵⁸

5 | CONSEQUENCES OF DEVELOPMENTAL ORIGINS ON HAIR FOLLICLE MINIATURISATION

In this viewpoint so far, we have postulated that the different developmental origins of the skin dermis on the scalp facilitate the observed differences in androgen sensitivity. Besides from androgen sensitivity, MPHL can be characterised by three other defining features: a decrease in anagen duration, a decline in hair fibre diameter, and longer latency periods (kenogen) between fibre shedding and regrowth.⁵⁹ The ratio of large (terminal) to small (including both miniaturised and vellus) follicles is <3:1 in MPHL, while this value can be greater than 7:1 in men without MPHL.⁶⁰

We propose that different developmental origins on the scalp and consequently differences in androgen sensitivity directly contribute to these other defining features seen in MPHL. While expression of the AR targets DKK-1 and TGF- β 1 inhibit proliferation of keratinocytes,^{61,62} expression of TGF- β 2 and IL-6 induces the early onset of catagen.^{63,64} This in turn leads to a shortening of anagen which relative to an equivalent length telogen reduces the anagen:telogen ratio of follicles on the scalp.⁶⁵ The anagen:telogen ratio varies between individuals (both non-balding and MPHL subjects) and between investigators using different methods of assessment. On a typical non-balding scalp one might find 90% of follicles are in anagen, 1% in catagen and 9% in telogen.³¹ Comparatively, in AGA the anagen:telogen ratio can decrease to 83:17.³¹ In the case of the greatest observed decrease in cycle duration in MPHL, frontal scalp follicles have an anagen phase of under 6 months⁵⁹ and a

telogen phase of 2–3 months, meaning that in individuals with MPHL follicles in the frontal balding zone cycle more frequently over a set duration of time (Figure 2). More specifically, the length of anagen in individuals with AGA has been noted to decrease by 20%–95% across 10 years, with the latency period (telogen and anagen combined) between cycles increasing between 10%–125%.⁵⁹ In miniaturised follicles with a 95% decrease in anagen duration and only a 10% latency increase, a follicle could be cycling around 9.4 times for every 1 cycle it would have previously undergone as a terminal follicle (Figure 2A).

6 | IS MPHL A FORM OF LOCALISED ACCELERATED AGEING?

So far in this piece, we have linked developmental origins and androgen sensitivity with an increased number of transitions through the hair follicle cycle in miniaturising follicles. A decreased anagen duration along with an increased latency period has also been identified in hair follicles with increasing chronological age.² The observations of perturbations to the follicle cycle in MPHL appear to manifest as an excessive version of those observed during normal hair follicle

ageing. But how do these changes to the hair follicle cycle lead to miniaturisation in MPHL?

In mice, at the start of each new anagen there is a division of dermal sheath stem cells that act as a fuel source to replenish the DP to its size during the previous anagen.³⁰ The increased frequency of cycling observed in MPHL must in turn impact the frequency at which the dermal sheath stem cells proliferate to replenish the DP at the start of anagen. Increased proliferation above the norm would lead to an increase in the epigenetic age of dermal sheath stem cells, and consequently the dermal papilla cells, in miniaturised follicles. This is a double-edged sword as a combination of follicular and more specifically stem cell ageing can contribute to dysfunction in self renewal and/or differentiation capacity.⁶⁶ Here, we hypothesise that MPHL is characterised by localised accelerated ageing of the hair follicle dermis, driven in response to signalling downstream of AR activation in frontal follicles. This hypothesis is supported by the observation of increased p16INK4a expression (a marker of senescence) in cultured balding DP versus non-balding DP cells from the same patient.⁶⁷

Lastly, during normal chronological ageing of murine hair follicles, several biologically repressive genes including *Cyr61* (senescence), *Egr1* (tumour suppressor), *Btg2* (anti-proliferation), *Gadd45g*




FIGURE 2 Is AGA a form of accelerated ageing? (A) Data from Courtois et al.,⁵⁹ was reanalysed to determine the impact of changes in cycle length in MPHL on the number of hair cycles across a 5 year time frame. (B) The signature of murine DP changes with increasing age. Schematic created with data from Shin et al.⁶⁸ (C) Genes such as EGR1 are found to be increased in expression in frontal DP versus occipital DP in humans (own unpublished data set).

(proliferation arrest) and *SocS3* (cytokine signalling repressor) are upregulated in their DP compared to young mouse DP (Figure 2B).⁶⁸ An upregulation of *Cyr61* leads to fibroblast senescence through p16INK4a activation. *EGR1* has also been associated with ageing in human haematopoietic stem cells,⁶⁹ and granulosa cell apoptosis which is a cause of ovary ageing.⁷⁰ In unpublished work from our research group we recently found a significant increase in *EGR1* expression in frontal human DP relative to occipital DP from matched patient samples (Figure 2C). This too, supports the concept that MPHL is a form of localised accelerated ageing. Should this be the case, MPHL could be not only a condition of hormonal imbalance, but also one of accelerated ageing, with the pool of potential therapeutics for the condition widening to include rejuvenation or senolytic therapies.

7 | CONCLUDING REMARKS

The pattern of follicle miniaturisation in MPHL being restricted to frontal scalp is an intriguing phenomenon. Here, we have presented our argument that this pattern is due to differences in AR activity, which is facilitated by the developmental origin of the DP. We propose that miniaturisation of follicles on the frontal scalp in response to androgens leads to localised ageing of the hair follicle dermis (dermal papilla and dermal sheath) which in turn exacerbates MPHL.

A crux of the matter which remains unanswered is whether the frontal scalp is of a mixed lineage. Should this be the case, is it the presence of mesodermal cells in the environment of ectodermal cells that alters androgen sensitivity across the scalp? We suggest this could be investigated by using induced pluripotent stem cell (iPSC) derived DP, which are formed exclusively via an ectodermal⁷¹ or mesodermal lineage,⁷² as well as a culture mixing the two. Differences in AR and other candidate genes identified above could be analysed in iPSC-derived DP from different lineages, to see if they resemble the differences in current profiles relating to AR expression and the balding state. It must be noted that iPSC-derived organoids remain in an early developmental state, however this could be the first step to begin correlating developmental origins with DP function. Should this be the case, maybe the differences observed are indeed caused by differing developmental origins of the DP. An alternative approach to investigating the lineage of frontal and occipital scalp would be to attempt to directly reprogramming fibroblasts obtained from the two regions into neurons. Ectodermal derived cells which are non-neuronal (e.g., keratinocytes) are not able to directly reprogram into neurons due to the presence of a trivalent motif suppressing the neuronal state,⁷³ hence should frontal scalp fibroblasts resist the reprogramming, they are likely to be of an ectodermal origin.

A final take home message from this piece relates to experimental design and reporting. We have argued throughout that miniaturisation occurs due to a different developmental origin of follicles on the frontal scalp and described how dermal papilla from frontal and occipital sites have different transcriptomes and respond

differently to therapeutics. When reporting results generated from follicles taken from the 'scalp', researchers should clearly define the location on the scalp from which the follicles were taken since as we have seen, this can have a dramatic effect on the interpretation of results.

AUTHOR CONTRIBUTIONS

Leah C. Redmond: Conceptualisation, data curation, investigation, visualisation, writing—original draft, review and editing. Summik Limbu: Data curation, investigation, visualisation, writing—review and editing. Andrew G. Messenger: Writing—review and editing. Bessam Farjo: Resources and writing—review and editing. Claire A. Higgins: Conceptualisation, data curation, supervision, visualisation, writing—original draft, review and editing.

ACKNOWLEDGEMENTS

This work was supported by an EPSRC iCASE award to CAH and an ISHRS grant to BF and SL.

CONFLICT OF INTEREST STATEMENT

There are no conflicts of interest within this manuscript.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

ORCID

Leah C. Redmond  <https://orcid.org/0000-0002-3370-3373>

Summik Limbu  <https://orcid.org/0009-0002-1388-5664>

Bessam Farjo  <https://orcid.org/0000-0002-8662-6316>

Andrew G. Messenger  <https://orcid.org/0000-0003-1424-8069>

Claire A. Higgins  <https://orcid.org/0000-0002-9742-5149>

REFERENCES

- Higgins CA, Westgate GE, Jahoda CAB. From telogen to exogen: mechanisms underlying formation and subsequent loss of the hair club fiber. *J Invest Dermatol.* 2009;129(9):2100-2108. doi:10.1038/jid.2009.66
- Courtois M, Loussouarn G, Hourseau C, Grollier JF. Ageing and hair cycles. *Br J Dermatol.* 1995;132(1):86-93. doi:10.1111/J.1365-2133.1995.TB08630.X
- Stene JJ. Hair physiology. *Rev Med Brux.* 2004;25(4):A282-A285.
- Norwood OT. Male pattern baldness: classification and incidence. *South Med J.* 1975;68(11):1359-1365. doi:10.1097/00007611-197511000-00009
- Piérard-Franchimont C, Piérard GE. Teloptosis, a turning point in hair shedding biorhythms. *Dermatology.* 2001;203(2):115-117. doi:10.1159/000051723
- Rebora A. Pathogenesis of androgenetic alopecia. *J Am Acad Dermatol.* 2004;50(5):777-779. doi:10.1016/j.jaad.2003.11.073
- Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. *J Am Acad Dermatol.* 2005;52(2):301-311. doi:10.1016/j.jaad.2004.04.008
- Jimenez F, Alam M, Vogel JE, Avram M. Hair transplantation: basic overview. *J Am Acad Dermatol.* 2021;85(4):803-814. doi:10.1016/j.jaad.2021.03.124

9. Hillmer AM, Brockschmidt FF, Hanneken S, et al. Susceptibility variants for male-pattern baldness on chromosome 20p11. *Nat Genet.* 2008;40(11):1279-1281. doi:10.1038/ng.228
10. Rui W, Sheng Y, Hu R, et al. Polymorphic CAG repeat numbers in the androgen receptor gene of female pattern hair loss in a Han Chinese population. *Dermatology.* 2016;232(4):464-467. doi:10.1159/000446648
11. Redler S, Messenger AG, Betz RC. Genetics and other factors in the aetiology of female pattern hair loss. *Exp Dermatol.* 2017;26(6):510-517. doi:10.1111/EXD.13373
12. Richards JB, Yuan X, Geller F, et al. Male-pattern baldness susceptibility locus at 20p11. *Nat Genet.* 2008;40(11):1282-1284. doi:10.1038/NG.255
13. Liang B, Yang C, Zuo X, et al. Genetic variants at 20p11 confer risk to androgenetic alopecia in the Chinese Han population. *PLoS One.* 2013;8(8):e71771. doi:10.1371/JOURNAL.PONE.0071771
14. Kim IY, Kim JH, Choi JE, et al. The first broad replication study of SNPs and a pilot genome-wide association study for androgenetic alopecia in Asian populations. *J Cosmet Dermatol.* 2022;21(11):6174-6183. doi:10.1111/JOCD.15187
15. Redler S, Brockschmidt FF, Tazi-Ahni R, et al. Investigation of the male pattern baldness major genetic susceptibility loci AR/EDA2R and 20p11 in female pattern hair loss. *Br J Dermatol.* 2012;166(6):1314-1318. doi:10.1111/J.1365-2133.2012.10877.X
16. Brockschmidt FF, Heilmann S, Ellis JA, et al. Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness. *Br J Dermatol.* 2011;165(6):1293-1302. doi:10.1111/J.1365-2133.2011.10708.X
17. Li R, Brockschmidt FF, Kiefer AK, et al. Six novel susceptibility loci for early-onset androgenetic alopecia and their unexpected association with common diseases. *PLoS Genet.* 2012;8(5):e1002746. doi:10.1371/JOURNAL.PGEN.1002746
18. Heilmann-Heimbach S, Herold C, Hochfeld LM, et al. Meta-analysis identifies novel risk loci and yields systematic insights into the biology of male-pattern baldness. *Nat Commun.* 2017;8:14694. doi:10.1038/NCOMMS14694
19. Hochfeld LM, Bertolini M, Broadley D, et al. Evidence for a functional interaction of WNT10A and EBF1 in male-pattern baldness. *PLoS One.* 2021;16(9):e0256846. doi:10.1371/JOURNAL.PONE.0256846
20. Hamilton JB. Effect of castration IN adolescent and young adult males upon further changes IN the proportions of bare and hairy scalp. *J Clin Endocrinol Metab.* 1960;20(10):1309-1318. doi:10.1210/JCEM-20-10-1309
21. Hamilton JB. Male hormone stimulation is prerequisite and an incitant in common baldness. *Am J Anat.* 1942;71(3):451-480. doi:10.1002/aja.1000710306
22. Shim J, Park J, Abudureyimu G, et al. Comparative spatial transcriptional and single-cell analyses of human nail units and hair follicles show transcriptional similarities between the onychodermis and follicular dermal papilla. *J Invest Dermatol.* 2022;142(12):3146-3157.e12. doi:10.1016/J.JID.2022.06.022
23. Kozłowska: the clinical picture and the treatment... - Google Scholar. Accessed April 14, 2022. [https://scholar.google.com/scholar_lookup?journal=Przegled+Dermatol&title=The+clinical+picture+and+the+treatment+of+the+most+common+form+of+alopecia+\[Polish\]&author=U+Koz%C5%82owska&author=A+Koz%C5%82owska&volume=4&publication_year=2001&pages=311-20&](https://scholar.google.com/scholar_lookup?journal=Przegled+Dermatol&title=The+clinical+picture+and+the+treatment+of+the+most+common+form+of+alopecia+[Polish]&author=U+Koz%C5%82owska&author=A+Koz%C5%82owska&volume=4&publication_year=2001&pages=311-20&)
24. Deng Z, Chen M, Liu F, et al. Androgen receptor-mediated paracrine signaling induces regression of blood vessels in the dermal papilla in androgenetic alopecia. *J Invest Dermatol.* 2022;142:2088-2099.e9. doi:10.1016/j.jid.2022.01.003
25. Yang YC, Fu HC, Wu CY, Wei KT, Huang KE, Kang HY. Androgen receptor accelerates premature senescence of human dermal papilla cells in association with DNA damage. *PLoS One.* 2013;8(11):e79434. doi:10.1371/journal.pone.0079434
26. Rompolas P, Deschene ER, Zito G, et al. Live imaging of stem cell and progeny behaviour in physiological hair-follicle regeneration. *Nature.* 2012;487(7408):496-499. doi:10.1038/NATURE11218
27. Legué E, Nicolas JF. Hair follicle renewal: organization of stem cells in the matrix and the role of stereotyped lineages and behaviors. *Development.* 2005;132(18):4143-4154. doi:10.1242/dev.01975
28. Jahoda CAB, Horne KA, Oliver RF. Induction of hair growth by implantation of cultured dermal papilla cells. *Nature.* 1984;311(5986):560-562. doi:10.1038/311560A0
29. Elliott K, Stephenson TJ, Messenger AG. Differences in hair follicle dermal papilla volume are due to extracellular matrix volume and cell number: implications for the control of hair follicle size and androgen responses. *J Invest Dermatol.* 1999;113(6):873-877. doi:10.1046/J.1523-1747.1999.00797.X
30. Rahmani W, Abbasi S, Hagner A, et al. Hair follicle dermal stem cells regenerate the dermal sheath, repopulate the dermal papilla, and modulate hair type. *Dev Cell.* 2014;31(5):543-558. doi:10.1016/J.DEVCEL.2014.10.022
31. Whiting DA. Male pattern hair loss: current understanding. *Int J Dermatol.* 1998;37(8):561-566. doi:10.1046/j.1365-4362.1998.00542.x
32. Pantelireis N, Higgins CA. A bald statement - current approaches to manipulate miniaturisation focus only on promoting hair growth. *Exp Dermatol.* 2018;27(9):959-965. doi:10.1111/exd.13690
33. Torkamani N, Rufaut NW, Jones L, Sinclair R. Destruction of the arrector pili muscle and fat infiltration in androgenic alopecia. *Br J Dermatol.* 2014;170(6):1291-1298. doi:10.1111/BJD.12921
34. Torkamani N, Rufaut NW, Jones L, Sinclair RD. Beyond goosebumps: does the arrector pili muscle have a role in hair loss? *Int J Trichology.* 2014;6(3):88-94. doi:10.4103/0974-7753.139077
35. Narisawa Y, Kohda H. Arrector pili muscles surround human facial vellus hair follicles. *Br J Dermatol.* 1993;129(2):138-139. doi:10.1111/J.1365-2133.1993.TB03515.X
36. Fujiwara H, Ferreira M, Donati G, et al. The basement membrane of hair follicle stem cells is a muscle cell niche. *Cell.* 2011;144(4):577-589. doi:10.1016/J.CELL.2011.01.014
37. Garza LA, Yang CC, Zhao T, et al. Bald scalp in men with androgenic alopecia retains hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor cells. *J Clin Invest.* 2011;121(2):613-622. doi:10.1172/JCI44478
38. Sawaya ME, Price VH. Different levels of 5 α -reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. *J Invest Dermatol.* 1997;109(3):296-300. doi:10.1111/1523-1747.ep12335779
39. Orentreich N. Autografts in ALOPECIAS and other selected dermatological conditions. *Ann N Y Acad Sci.* 1959;83(3):463-479. doi:10.1111/J.1749-6632.1960.TB40920.X
40. Ando Y, Yamaguchi Y, Hamada K, Yoshikawa K, Itami S. Expression of mRNA for androgen receptor, 5 α -reductase and 17 β -hydroxysteroid dehydrogenase in human dermal papilla cells. *Br J Dermatol.* 1999;141(5):840-845. doi:10.1046/j.1365-2133.1999.03156.x
41. Randall VA, Hibberts NA, Thornton MJ, et al. The hair follicle: a paradoxical androgen target organ. *Hormone Res.* 2000;54:243-250. doi:10.1159/000053266
42. Midorikawa T, Chikazawa T, Yoshino T, Takada K, Arase S. Different gene expression profile observed in dermal papilla cells related to androgenic alopecia by DNA microarray analysis. *J Dermatol Sci.* 2004;36(1):25-32. doi:10.1016/J.JDERMSCI.2004.05.001
43. Chew EGY, Tan JHJ, Bahta AW, et al. Differential expression between human dermal papilla cells from balding and non-balding scalps reveals new candidate genes for androgenetic alopecia. *J Invest Dermatol.* 2016;136(8):1559-1567. doi:10.1016/J.JID.2016.03.032

44. Kwack MH, Ahn JS, Jang JH, Kim JC, Sung YK, Kim MK. SFRP2 augments Wnt/ β -catenin signalling in cultured dermal papilla cells. *Exp Dermatol*. 2016;25(10):813-815. doi:10.1111/EXD.12993
45. Sato T, Tadokoro T, Sonoda T, Asada Y, Itami S, Takayasu S. Minoxidil increases 17 β -hydroxysteroid dehydrogenase and 5 α -reductase activity of cultured human dermal papilla cells from balding scalp. *J Dermatol Sci*. 1999;19(2):123-125. doi:10.1016/S0923-1811(98)00048-6
46. Driskell RR, Lichtenberger BM, Hoste E, et al. Distinct fibroblast lineages determine dermal architecture in skin development and repair. *Nature*. 2013;504(7479):277-281. doi:10.1038/NATURE12783
47. Sengel P, Mauger A. Peridermal cell patterning in the feather-forming skin of the chick embryo. *Dev Biol*. 1976;51(1):166-171. doi:10.1016/0012-1606(76)90132-9
48. Ohtola J, Myers J, Akhtar-Zaidi B, et al. Beta-catenin has sequential roles in the survival and specification of ventral dermis. *Development*. 2008;135(13):2321-2329. doi:10.1242/DEV.021170
49. Nowicki JL, Takimoto R, Burke AC. The lateral somitic frontier: dorso-ventral aspects of antero-posterior regionalization in avian embryos. *Mech Dev*. 2003;120(2):227-240. doi:10.1016/S0925-4773(02)00415-X
50. Couly GF, Coltey PM, le Douarin NM. The triple origin of skull in higher vertebrates: a study in quail-chick chimeras. *Development*. 1993;117(2):409-429. doi:10.1242/dev.117.2.409
51. Jiang X, Iseki S, Maxson RE, Sucov HM, Morriss-Kay GM. Tissue origins and interactions in the mammalian skull vault. *Dev Biol*. 2002;241(1):106-116. doi:10.1006/DBIO.2001.0487
52. Yoshida T, Vivatbutsi P, Morriss-Kay G, Saga Y, Iseki S. Cell lineage in mammalian craniofacial mesenchyme. *Mech Dev*. 2008;125(9-10):797-808. doi:10.1016/J.MOD.2008.06.007
53. le Douarin NM, Ziller C, Couly GF. Patterning of neural crest derivatives in the avian embryo: in vivo and in vitro studies. *Dev Biol*. 1993;159(1):24-49. doi:10.1006/dbio.1993.1219
54. le Douarin N, Kalcheim C. *The Neural Crest*. Cambridge University Press; 1999. doi:10.1017/cbo9780511897948
55. le Lievre CS. Participation of neural crest-derived cells in the genesis of the skull in birds. *J Embryol Exp Morphol*. 1978;47:17-37. doi:10.1242/dev.47.1.17
56. Philippeos C, Telerman SB, Oulès B, et al. Spatial and single-cell transcriptional profiling identifies functionally distinct human dermal fibroblast subpopulations. *J Invest Dermatol*. 2018;138(4):811-825. doi:10.1016/J.JID.2018.01.016
57. Rinn JL, Bondre C, Gladstone HB, Brown PO, Chang HY. Anatomic demarcation by positional variation in fibroblast gene expression programs. *PLoS Genet*. 2006;2(7):1084-1096. doi:10.1371/JOURNAL.PGEN.0020119
58. Jahoda CAB. Induction of follicle formation and hair growth by vibrissa dermal papillae implanted into rat ear wounds: vibrissa-type fibres are specified. *Development*. 1992;115(4):1103-1109. doi:10.1242/DEV.115.4.1103
59. Courtois M, Loussouarn G, Hourseau C, Grollier JF. Hair cycle and alopecia. *Skin Pharmacol Physiol*. 1994;7(1-2):84-89. doi:10.1159/000211279
60. Blume-Peytavi U, Blumeyer A, Tosti A, et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. *Br J Dermatol*. 2011;164(1):5-15. doi:10.1111/J.1365-2133.2010.10011.X
61. Kwack MH, Sung YK, Chung EJ, et al. Dihydrotestosterone-inducible dickkopf 1 from balding dermal papilla cells causes apoptosis in follicular keratinocytes. *J Invest Dermatol*. 2008;128(2):262-269. doi:10.1038/sj.jid.5700999
62. Inui S, Fukuzato Y, Nakajima T, Yoshikawa K, Itami S. Androgen-inducible TGF- β 1 from balding dermal papilla cells inhibits epithelial cell growth: a clue to understand paradoxical effects of androgen on human hair growth. *FASEB J*. 2002;16(14):1967-1969. doi:10.1096/fj.02-0043fje
63. Kwack MH, Kim MK, Kim JC, Sung YK. Dickkopf 1 promotes regression of hair follicles. *J Invest Dermatol*. 2012;132(6):1554-1560. doi:10.1038/JID.2012.24
64. Hibino T, Nishiyama T. Role of TGF- β 2 in the human hair cycle. *J Dermatol Sci*. 2004;35(1):9-18. doi:10.1016/j.jdermsci.2003.12.003
65. Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: pathogenesis and potential for therapy. *Expert Rev Mol Med*. 2002;4(22):1-11. doi:10.1017/S1462399402005112
66. Jones DL, Rando TA. Emerging models and paradigms for stem cell ageing. *Nat Cell Biol*. 2011;13(5):506-512. doi:10.1038/NCB0511-506
67. Bahta AW, Farjo B, Philpott MP. Premature senescence of balding dermal papilla cells in vitro is associated with p16INK4a expression. *J Invest Dermatol*. 2008;128(5):1088-1094. doi:10.1038/sj.jid.5701147
68. Shin W, Rosin NL, Labit E, Stratton JA, Correspondence JB. Dysfunction of hair follicle mesenchymal progenitors contributes to age-associated hair loss. *Dev Cell*. 2020;53:185-198.e7. doi:10.1016/j.devcel.2020.03.019
69. Desterke C, Bennaceur-Griscelli A, Turhan AG. EGR1 dysregulation defines an inflammatory and leukemic program in cell trajectory of human-aged hematopoietic stem cells (HSC). *Stem Cell Res Ther*. 2021;12(1):419. doi:10.1186/S13287-021-02498-0
70. Yuan S, Wen J, Cheng J, et al. Age-associated up-regulation of EGR1 promotes granulosa cell apoptosis during follicle atresia in mice through the NF- κ B pathway. *Cell Cycle*. 2016;15(21):2895-2905. doi:10.1080/15384101.2016.1208873
71. Veraitch O, Kobayashi T, Imaizumi Y, et al. Human induced pluripotent stem cell-derived ectodermal precursor cells contribute to hair follicle morphogenesis in vivo. *J Invest Dermatol*. 2013;133(6):1479-1488. doi:10.1038/jid.2013.7
72. Veraitch O, Mabuchi Y, Matsuzaki Y, et al. Induction of hair follicle dermal papilla cell properties in human induced pluripotent stem cell-derived multipotent LNGFR(+)/THY-1(+) mesenchymal cells. *Sci Rep*. 2017;7:7. doi:10.1038/srep42777
73. Wapinski OL, Vierbuchen T, Qu K, et al. Hierarchical mechanisms for transcription factor-mediated reprogramming of fibroblasts to neurons. *Cell*. 2013;155(3):621-635. doi:10.1016/J.CELL.2013.09.028

How to cite this article: Redmond LC, Limbu S, Farjo B, Messenger AG, Higgins CA. Male pattern hair loss: Can developmental origins explain the pattern? *Exp Dermatol*. 2023;00:1-8. doi:10.1111/exd.14839

THE OPPORTUNITY FOR COMPLETE, FAST AND LASTING SKIN CLEARANCE^{1,2}

- In phase III studies BIMZELX demonstrated superiority vs ustekinumab (BE VIVID; $p < 0.0001$), placebo (BE READY; $p < 0.0001$) and adalimumab (BE SURE; $p < 0.001$) in achieving the co-primary endpoints PASI 90 and IGA 0/1 at week 16 with 85% (273/321), 90.8% (317/349) and 86.2% (275/319) of patients achieving PASI 90 at Week 16. At Week 4, 76.9% (247/321), 75.9% (265/349) and 76.5% (244/319) of patients achieved the secondary endpoint of PASI 75.¹
- In the BE BRIGHT open label extension study, 62.7% (620/989) of patients achieved PASI 100 at Week 16 (non-responder imputation [NRI]). Of these patients, 84.4% (147/174) of patients randomised to 8 week dosing maintained PASI 100 at Week 148.²

Challenge expectations in psoriasis^{1,2}

Discover more

This site contains promotional information on UCB products.



To hear about future UCB projects, educational events and to receive the latest information from UCB, please scan the QR code set your digital preferences.



Use this QR code to access [Bimzelx.co.uk](https://bimzelx.co.uk)

BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.¹

Prescribing Information and Adverse Event can be found below.

Note: The most frequently reported adverse reactions with BIMZELX are: upper respiratory tract infections (14.5%) and oral candidiasis (7.3%).¹ Other common adverse events include: Tinea infection, ear infection, Herpes simplex infections, oropharyngeal candidiasis, gastroenteritis, folliculitis, headache, dermatitis and eczema, acne, injection site reaction and fatigue.

PRESCRIBING INFORMATION

(Please consult the Summary of Product Characteristics (SmPC) before prescribing)

BIMZELX[®] ▼ (Bimekizumab)

Active Ingredient: Bimekizumab – solution for injection in pre-filled syringe or pre-filled pen: 160 mg of bimekizumab in 1 mL of solution (160mg/mL). **Indications:** Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. **Dosage and Administration:** Should be initiated and supervised by a physician experienced in the diagnosis and treatment of plaque psoriasis. **Recommended dose:** 320 mg (given as two subcutaneous injections of 160 mg each) at week 0, 4, 8, 12, 16 and every 8 weeks thereafter. For some patients with a body weight ≥ 120 kg who did not achieve complete skin clearance at week 16, 320 mg every 4 weeks after week 16 may further improve treatment response. Consider discontinuing if no improvement by 16 weeks of treatment. Renal or hepatic impairment: No dose adjustment needed. Elderly: No dose adjustment needed. Administer by subcutaneous injection to thigh, abdomen or upper arm. Rotate injection sites and do not inject into psoriatic plaques or skin that is tender, bruised, erythematous or indurated. Do not shake pre-filled syringe or pre-filled pen. Patients may be trained to self-inject. **Contraindications:** Hypersensitivity to bimekizumab or any excipient; Clinically important active infections (e.g. active tuberculosis). **Warnings and Precautions:** Record name and batch number of administered product. **Infection:** Bimekizumab may increase the risk of infections e.g. upper respiratory tract infections, oral candidiasis. Caution when considering use in patients with a chronic infection or a history of recurrent infection. Must not be initiated if any clinically important active infection until infection resolves or is adequately treated. Advise patients to seek medical advice if signs or symptoms suggestive of an infection occur. If a clinically important infection develops or is not responding to standard therapy,

carefully monitor and do not administer bimekizumab until infection resolves. **TB:** Evaluate for TB infection prior to initiating bimekizumab – do not give if active TB. While on bimekizumab, monitor for signs and symptoms of active TB. Consider anti-TB therapy prior to bimekizumab initiation if past history of latent or active TB in whom adequate treatment course cannot be confirmed. **Inflammatory bowel disease:** Bimekizumab is not recommended in patients with inflammatory bowel disease. Cases of new or exacerbations of inflammatory bowel disease have been reported. If inflammatory bowel disease signs/symptoms develop or patient experiences exacerbation of pre-existing inflammatory bowel disease, discontinue bimekizumab and initiate medical management. **Hypersensitivity:** Serious hypersensitivity reactions including anaphylactic reactions have been observed with IL-17 inhibitors. If a serious hypersensitivity reaction occurs, discontinue immediately and treat. **Vaccinations:** Complete all age appropriate immunisations prior to bimekizumab initiation. Do not give live vaccines to bimekizumab patients. Patients may receive inactivated or non-live vaccinations. **Interactions:** A clinically relevant effect on CYP450 substrates with a narrow therapeutic index in which the dose is individually adjusted e.g. warfarin, cannot be excluded. Therapeutic monitoring should be considered. **Fertility, pregnancy and lactation:** Women of child-bearing potential should use an effective method of contraception during treatment and for at least 17 weeks after treatment. Avoid use of bimekizumab during pregnancy and breastfeeding. Discontinue breastfeeding or discontinue bimekizumab during breastfeeding. It is unknown whether bimekizumab is excreted in human milk, hence a risk to the newborn/infant cannot be excluded. No data available on human fertility. **Driving and use of machines:** No or negligible influence on ability to drive and use machines. **Adverse Effects: Refer to SmPC for full information.** Very Common ($\geq 1/10$): upper respiratory tract

infection; Common ($\geq 1/100$ to $< 1/10$): oral candidiasis, tinea infections, ear infections, herpes simplex infections, oropharyngeal candidiasis, gastroenteritis, folliculitis; headache, dermatitis and eczema, acne, injection site reactions, fatigue; Uncommon ($\geq 1/1,000$ to $< 1/100$): mucosal and cutaneous candidiasis (including oesophageal candidiasis), conjunctivitis, neutropenia, inflammatory bowel disease. **Storage precautions:** Store in a refrigerator (2°C – 8°C), do not freeze. Keep in outer carton to protect from light. Bimzelx can be kept at up to 25°C for a single period of maximum 25 days with protection from light. Product should be discarded after this period or by the expiry date, whichever occurs first.

Legal Category: POM

Marketing Authorisation Numbers:

Northern Ireland: EU/1/21/1575/002 (2 x 1 Pre-filled Syringes), EU/1/21/1575/006 (2 x 1 Pre-filled Pens) Great Britain: PLGB 00039/0802 (Pre-filled Syringe), PLGB 00039/0803 (Pre-filled Pen). UK NHS Costs: £2,443 per pack of 2 pre-filled syringes or pens of 160 mg each.

Marketing Authorisation Holder: UCB Pharma S.A., Allée de la Recherche 60, B-1070 Brussels, Belgium (Northern Ireland). UCB Pharma Ltd, 208 Bath Road, Slough, Berkshire, SL1 3WE, United Kingdom (Great Britain).

Further information is available from: UCB Pharma Ltd, 208 Bath Road, Slough, Berkshire, SL1 3WE.

Tel: +44 (0)1753 777100 Email: ucbcares.uk@ucb.com

Date of Revision: September 2021 IE-P-BK-PSO-2100102

Bimzelx is a registered trademark.

UK: Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to UCB Pharma Ltd.

References: 1. BIMZELX (bimekizumab) Summary of Product Characteristics. Available from: <https://www.medicines.org.uk/emc/product/12834/smpc>. Accessed April 2023. 2. Strober B et al. Poster P1491 presented at the European Academy of Dermatology and Venereology (EADV) meeting, September 7–10 2022; Milan, Italy.

IE-P-BK-PSO-2300070 Date of preparation: April 2023.

© UCB Biopharma SRL, 2023. All rights reserved.

BIMZELX[®] is a registered trademark of the UCB Group of Companies.



Inspired by patients.
Driven by science.